Relmada Therapeutics Stock Investor Sentiment
| RLMD Stock | USD 3.02 0.12 4.14% |
About 71 percent of all Relmada Therapeutics' shareholders are curious in acquiring. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
Relmada |
Relmada Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.
Relmada Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Insiders Who Purchased US663.4k Of Relmada Therapeutics Stock May Not Have Expected 14 percent Tumble | 09/06/2024 |
2 | Acquisition by Kelly Paul Edward of 25000 shares of Relmada Therapeutics at 2.59 subject to Rule 16b-3 | 09/09/2024 |
3 | Acquisition by Shenouda Maged of 21118 shares of Relmada Therapeutics at 2.73 subject to Rule 16b-3 | 09/10/2024 |
4 | Acquisition by Shenouda Maged of 24120 shares of Relmada Therapeutics at 2.95 subject to Rule 16b-3 | 09/11/2024 |
5 | Insider Spends US395k Buying More Shares In Relmada Therapeutics | 09/13/2024 |
6 | Relmada stock jumps as Jefferies upgrades | 09/17/2024 |
7 | Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3 | 10/16/2024 |
8 | Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3 | 10/22/2024 |
9 | Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3 | 10/28/2024 |
10 | Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 | 11/04/2024 |
11 | Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ... | 11/08/2024 |
12 | Relmada Therapeutics to Present at Jefferies London Healthcare Conference | 11/19/2024 |
13 | Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3 | 11/20/2024 |
Complementary Tools for Relmada Stock analysis
When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |